bioAffinity publishes clinical framework targeting pulmonary nodule risk stratification market
BIAF•Clinical framework centers on CyPath Lung
bioAffinity Technologies published a clinical review outlining a framework for pulmonary nodule risk stratification using its CyPath Lung test.
- Analysis flags rising demand as lung screening expands, incidental nodules increase, AI detection grows, and more survivors require long-term surveillance.
- Framework targets adoption in primary care, pulmonology nodule programs, interventional pulmonology, and oncology surveillance workflows.
- CyPath Lung is positioned as a noninvasive sputum-based tool to complement imaging and predictive models, aiming to reduce unnecessary invasive procedures.
